TimesSquare Capital Management LLC Raises Position in Vericel Corporation $VCEL

TimesSquare Capital Management LLC grew its stake in Vericel Corporation (NASDAQ:VCEL) by 12.6% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 836,861 shares of the biotechnology company’s stock after purchasing an additional 93,472 shares during the quarter. TimesSquare Capital Management LLC owned approximately 1.66% of Vericel worth $26,336,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of VCEL. Abich Financial Wealth Management LLC bought a new position in Vericel during the 3rd quarter valued at $31,000. CWM LLC lifted its position in shares of Vericel by 101.3% during the second quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 694 shares in the last quarter. AlphaQuest LLC purchased a new position in Vericel during the second quarter worth about $60,000. Osaic Holdings Inc. grew its position in Vericel by 13.7% in the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 353 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its stake in Vericel by 178.4% in the 2nd quarter. Smartleaf Asset Management LLC now owns 3,241 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 2,077 shares during the last quarter.

Vericel Trading Up 5.9%

Vericel stock opened at $35.96 on Friday. The business’s 50 day simple moving average is $37.00 and its 200 day simple moving average is $36.08. Vericel Corporation has a 12 month low of $29.24 and a 12 month high of $58.77. The company has a market cap of $1.82 billion, a price-to-earnings ratio of 149.84 and a beta of 1.24.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on VCEL shares. Truist Financial cut their target price on Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Vericel in a report on Monday, December 29th. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Finally, Zacks Research cut Vericel from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Vericel Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.